Lectin‐Like Oxidized Low‐Density Lipoprotein Receptor 1 Inhibition in Type 2 Diabetes: Phase 1 Results

BACKGROUND: Blockade of the lectin‐like oxidized low‐density lipoprotein receptor‐1 (LOX‐1) is a potentially attractive mechanism for lowering inflammatory and lipid risk in patients with atherosclerosis. This study aims to assess the safety, tolerability, and target engagement of MEDI6570, a high‐a...

Descripción completa

Detalles Bibliográficos
Autores principales: Vavere, Andrea L., Sinsakul, Marvin, Ongstad, Emily L., Yang, Ye, Varma, Vijayalakshmi, Jones, Christopher, Goodman, Joanne, Dubois, Vincent F. S., Quartino, Angelica L., Karathanasis, Sotirios K., Abuhatzira, Liron, Collén, Anna, Antoniades, Charalambos, Koren, Michael J., Gupta, Ruchi, George, Richard T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973634/
https://www.ncbi.nlm.nih.gov/pubmed/36688371
http://dx.doi.org/10.1161/JAHA.122.027540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973634/
https://www.ncbi.nlm.nih.gov/pubmed/36688371
http://dx.doi.org/10.1161/JAHA.122.027540

Ejemplares similares